Skip to main content
. 2016 Oct 21;7(48):78713–78725. doi: 10.18632/oncotarget.12805

Figure 5. Correlation of SIN3 paralog expression in patients with breast cancer.

Figure 5

(A, B) Five-year relapse-free survival rates for all breast cancers with high and low expression of SIN3A (A) and SIN3B (B) generated with the public database kmplot.com (hazard ratios = 0.58 and 0.49; logrank P = 7.8e-10 and < 1e-16 respectively for SIN3A and SIN3B). (C–F) Five-year relapse-free survival rates specifically in patients with triple-negative breast cancer with high and low expression of SIN3A (C,E) and SIN3B (D,F) using kmplot. com (C,D) and PROGgenV2 (E,F). High expression of SIN3A and low expression of SIN3B correlated with a longer relapse-free survival specifically in triple negative breast cancers (hazard ratios = 0.56 and 1.51; logrank P = 0.055 and 0.076 respectively for SIN3A and SIN3B using kmplot.com in C,D and hazard ratios = 0.35 and 2.66; logrank P = 0.0489 and 0.0587 respectively for SIN3A and SIN3B using PROGgeneV2 in E,F). Oncomine analysis of normal breast samples compared to invasive ductal carcinoma (IDC) shows increases in the expression of SIN3A (G) and SIN3B (H) (p = 4.11E-8 and p = 5.56E-29, respectively for SIN3A and SIN3B). However, a trend is noted for decreased SIN3A expression (I) p = 0.084) and increased SIN3B expression (J) p = 0.205) in patients with IBC compared to ductal carcinoma in situ (DCIS).